Osetron (Ondansetron Hydrochloride Dihydrate)

Ondansetron, the active ingredient in Osetron, is a 5-HT3 receptor antagonist presented as a tablet for oral use. It treats and helps prevent nausea and vomiting associated with chemotherapy, radiation therapy, and postoperative recovery in adult and pediatric patients.

GNH USA supplies Osetron as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Osetron is a selective 5‑HT3 receptor antagonist used in the management of nausea and vomiting across several clinical pathways. - Chemotherapy‑induced nausea and vomiting: reduces the frequency and severity of acute episodes. - Radiation‑induced nausea and vomiting: helps control symptoms during and after radiotherapy. - Post‑operative nausea and vomiting: decreases incidence of vomiting after surgical procedures. - Pregnancy‑associated hyperemesis gravidarum (when other therapies are ineffective): provides symptom relief under specialist supervision.

Adverse reactions to Osetron are generally mild to moderate, but clinicians monitor patients for both common and rare events.

Common Side Effects: - Headache: mild to moderate intensity. - Constipation: reduced bowel movements. - Diarrhoea: loose stools. - Fatigue: feeling of tiredness. - Dizziness: transient light‑headedness.

Serious or Rare Side Effects: - QT interval prolongation: cardiac rhythm changes detectable on ECG. - Severe allergic reaction: rash, itching, swelling, or anaphylaxis. - Hepatic enzyme elevation: increased liver function test values. - Serotonin syndrome: rare when combined with other serotonergic agents. - Vision changes: blurred vision or transient visual disturbances.

Before prescribing Osetron, clinicians consider several safety factors. - Cardiac monitoring: assess baseline ECG in patients with known cardiac disease. - Electrolyte balance: correct hypokalaemia or hypomagnesemia to reduce QT risk. - Liver function: evaluate hepatic impairment and adjust use accordingly. - Concomitant serotonergic drugs: avoid or monitor for serotonin syndrome. - Pregnancy and lactation: weigh benefits against potential risks; use only if clearly needed. - Store at ambient temperature: keep below 25 °C, retain in original container, protect from moisture and direct sunlight.

Ondansetron may interact with several medicines, requiring attention to the interaction severity.

Major Interactions (Avoid): - Amiodarone: combined use can markedly increase QT prolongation risk. - Certain anti‑arrhythmics (e.g., sotalol, quinidine): additive cardiac conduction effects. - Tramadol and other serotonergic analgesics: heightened risk of serotonin syndrome.

Moderate Interactions (Monitor Closely): - Antifungal azoles (e.g., fluconazole, ketoconazole): may raise ondansetron plasma levels. - Macrolide antibiotics (e.g., erythromycin): modest increase in QT interval. - CYP3A4 inhibitors (e.g., diltiazem): can affect drug metabolism. - Oral contraceptives: slight reduction in hormonal efficacy. - Diuretics causing electrolyte loss: monitor potassium and magnesium levels.